Alpe lisib trifluoromethylbenzoate was developed by Novartis and is in Phase III clinical trials for the treatment of breast cancer. The research of Alpelisib for the treatment of non-small cell lung cancer is in the clinical phase II. The research of Alpelisib for the treatment of colorectal cancer, head and neck cancer, multiple myeloma, esophageal cancer and solid tumors is in the clinical phase I and II. The research on the treatment of gastric cancer, gastrointestinal stromal tumor, pancreatic cancer and uveal melanoma with hydroxysulfone is in the first clinical phase. Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with an IC50 of 5nM in cell-free assays and a very weak effect on PI3Kβ/γ/δ.
TAG：Alpelisib (BYL719),Alpelisib ,BYL719,
